Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cotinga Pharmaceuticals Inc COTQF

Healthcare Biotechnology
Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up to 30% of all cancers.


GREY:COTQF - Post by User

Cotinga Pharmaceuticals Inc
Bullboard Posts
User Avatar Image
(325)
•••
Comment by Actuarialon May 23, 2017 9:36am
90 Views
Post# 26272168

RE:RE:RE:RE:What do you expect? Useless Female CEO

RE:RE:RE:RE:What do you expect? Useless Female CEO
fatladysings321 wrote:
but the COT timeline was to be like this.


Nope, if you truly follow the company, you would know that COT should have already completed cohort four in 2016. Almost half year of 2017 passed, we haven't heard anything about cohort four results yet. And you call its timeline was to be like this?
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities